Antibodies News and Research

RSS

Scientists identify how molecular motor essential for human development works

Another mystery of the human body has been solved by scientists who have identified how a molecular motor essential for human development works.

10 Sep 2014

Researchers aim to safely and quickly suppress food allergies in human

In mice, the answer appears to be "yes," but making sure the same can happen in humans is a task that Fred Finkelman, MD, professor of medicine and pediatrics in the University of Cincinnati's (UC) College of Medicine and a researcher at Cincinnati Children's Hospital Medical Center, is attempting to tackle.

9 Sep 2014

SLU researchers work to prevent several serious infectious diseases

Saint Louis University researchers are attacking influenza on multiple fronts as they search for a universal vaccine that protects people from the flu virus that often mutates year to year with deadly consequences.

9 Sep 2014

New discovery could help efforts to produce more effective vaccines

The best defense is a good offense, especially when it comes to the immune system. The troops that respond to an infection are split into two squadrons, and, until recently, it seemed that the two were independent, without much interaction.

9 Sep 2014

Canada funds 22 inventive ideas for improving health in low-resource countries

Grand Challenges Canada, funded by the Government of Canada, today announced $2.4 million in seed funds shared between 22 projects from Canada and nine developing nations, to pursue inventive new ideas for improving health in low-resource countries.

8 Sep 2014

Restarting infliximab therapy after drug holiday is safe for patients with IBD

Restarting infliximab therapy after a drug holiday is safe and effective for patients with inflammatory bowel disease (IBD), according to a new study1 in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

8 Sep 2014

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin).

8 Sep 2014

New antibody in HIV-infected person binds to virus

An NIH-led team of scientists has discovered a new vulnerability in the armor of HIV that a vaccine, other preventive regimen or treatment could exploit.

4 Sep 2014

New way to reduce abnormal blood vessel growth and leakage in eye

Working with mice, a multicenter team of researchers has found a new way to reduce the abnormal blood vessel growth and leakage in the eye that accompany some eye diseases. The finding could lead to the development of new drugs for wet macular degeneration and diabetic macular edema.

4 Sep 2014

Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine, in partnership with the California Institute for Regenerative Medicine (CIRM) and Celgene Corporation, a New Jersey-based biopharmaceutical company, have launched a phase 1 human clinical trial to assess the safety and efficacy of a novel monoclonal antibody for patients with chronic lymphocytic leukemia (CLL).

4 Sep 2014

Artificial cells to devour undesirables: an interview with Dr. Takanari Inoue

If junk is not removed, pathological conditions can develop. For example, in one condition, the neutrophil count significantly decreases. Neutrophils remove pathogens and people with a reduced neutrophil count are more prone to infection, especially to rare bacteria that wouldn’t cause infection under normal conditions.

3 Sep 2014

Clinical studies to treat unmet medical need post-transplantation

A class of biotechnology drugs called monoclonal antibodies is now being tested in clinical studies to treat an unmet medical need post-transplantation, called delayed graft function

3 Sep 2014

XBiotech reports interim results from Phase III study for anti-cancer agent Xilonix

XBiotech announced today interim results from its fast-tracked Phase III study being conducted in the US for its anti-cancer agent Xilonix.

2 Sep 2014

BioLegend acquires shares of Covance Antibody Services

BioLegend, Inc. (BioLegend) acquired the shares of Covance Antibody Services Inc., a business unit of Covance, located in Dedham, Massachusetts, on August 29, 2014.

From BioLegend 2 Sep 2014

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its final preclinical toxicology study of SYN-004.

2 Sep 2014

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin toxin vaccine RiVax™, in a non-human primate (NHP) lethal aerosol exposure model.

2 Sep 2014

Scientists develop synthetic amino acid that can impact 3D structure of bioactive peptides

One of the greatest challenges in modern medicine is developing drugs that are highly effective against a target, but with minimal toxicity and side-effects to the patient. Such properties are directly related to the 3D structure of the drug molecule.

1 Sep 2014

Blend of three monoclonal antibodies can protect monkeys against Ebola virus, says UTMB researcher

A leading U.S. Ebola researcher from the University of Texas Medical Branch at Galveston has gone on record stating that a blend of three monoclonal antibodies can completely protect monkeys against a lethal dose of Ebola virus up to 5 days after infection, at a time when the disease is severe.

30 Aug 2014

Gene therapy may offer significant advantages in prevention of botulism exposure

The current method to treat acute toxin poisoning is to inject antibodies, commonly produced in animals, to neutralize the toxin. But this method has challenges ranging from safety to difficulties in developing, producing and maintaining the anti-serums in large quantities.

30 Aug 2014

Researchers find method to expand blood stem cells used to treat cancer patients

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients.

30 Aug 2014

Antibodies News and Research

Scientists identify how molecular motor essential for human development works

Researchers aim to safely and quickly suppress food allergies in human

SLU researchers work to prevent several serious infectious diseases

New discovery could help efforts to produce more effective vaccines

Canada funds 22 inventive ideas for improving health in low-resource countries

Restarting infliximab therapy after drug holiday is safe for patients with IBD

Soligenix acquires novel orphan drug candidate for treatment of CTCL

New antibody in HIV-infected person binds to virus

New way to reduce abnormal blood vessel growth and leakage in eye

Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Artificial cells to devour undesirables: an interview with Dr. Takanari Inoue

Clinical studies to treat unmet medical need post-transplantation

XBiotech reports interim results from Phase III study for anti-cancer agent Xilonix

BioLegend acquires shares of Covance Antibody Services

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Scientists develop synthetic amino acid that can impact 3D structure of bioactive peptides

Blend of three monoclonal antibodies can protect monkeys against Ebola virus, says UTMB researcher

Gene therapy may offer significant advantages in prevention of botulism exposure

Researchers find method to expand blood stem cells used to treat cancer patients

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo